Livensa

RSS

testosterone

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Livensa has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 16/04/2012

Authorisation details

Product details
Name
Livensa
Agency product number
EMEA/H/C/000630
Active substance
Testosterone
International non-proprietary name (INN) or common name
testosterone
Therapeutic area (MeSH)
Sexual Dysfunctions, Psychological
Anatomical therapeutic chemical (ATC) code
G03BA03
Publication details
Marketing-authorisation holder
Warner Chilcott  Deutschland GmbH
Revision
6
Date of issue of marketing authorisation valid throughout the European Union
28/07/2006
Contact address
Warner Chilcott Deutschland GmbH
Dr.-Otto-Röhm-Strasse 2-4
D-64331 Weiterstadt
Germany

Product information

18/07/2011 Livensa - EMEA/H/C/000630 - R/0016

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Sex hormones and modulators of the genital system

Therapeutic indication

Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.

Assessment history

How useful was this page?

Add your rating